I-FDA ithi Ayifuni ukwamkela i-CBD njenge "Khuselekileyo"

Umxholo

• Iingozi ezinokuthi zenzeke kwi-CBD
• I-FDA isaphula njani i-CBD
• Yintoni omele uyazi Ukuqhubela phambili
• Uphengululo lwe

I-CBD ikuyo yonke indawo kule mihla. Ngaphezulu kokuchithwa njengonyango olunokubakho kulawulo lweentlungu, unxunguphalo, kunye nokunye, ikhompawundi ye-cannabis iye yahluma kuyo yonke into ukusuka emanzini aqaqambileyo, iwayini, ikofu kunye nezinto zokuthambisa, ukuya kwisini nakwimveliso yexesha. KwaneCVS kunye neeWalgreens ziqale ukuthengisa iimveliso ezifakwe yi-CBD kwiindawo ezikhethiweyo ebutsheni balo nyaka.

Kodwa uhlaziyo olutsha lomthengi oluvela kuLawulo lokutya kunye noLawulo lweziyobisi (i-FDA) ithi a okuninzi kufuneka kwenziwe uphando olungaphaya phambi kokuba i-CBD ithathwe njengekhuselekileyo. "Mininzi imibuzo engaphendulekiyo malunga nesayensi, ukhuseleko kunye nomgangatho weemveliso eziqukethe i-CBD," utshilo iarhente kuhlaziyo lwayo. "I-FDA ibone kuphela idatha ethintelweyo malunga nokhuseleko lwe-CBD kwaye ezi datha zikhomba kwimingcipheko yokwenyani ekufuneka ithathelwe ingqalelo ngaphambi kokuthatha i-CBD nangasiphi na isizathu."

Ukuthandwa okukhulayo kwe-CBD sesona sizathu siphambili sokuba i-FDA ikhethe ukukhupha esi silumkiso singqongqo kuluntu ngoku, ngokohlaziyo lwayo lwabathengi. Eyona nkxalabo inkulu ye-arhente? Uninzi lwabantu lukholelwa ukuba ukuzama i-CBD "akunakwenzakalisa," ngaphandle kokunqongophala kophando oluthembekileyo, oluqinisekileyo malunga nokhuseleko lwekhompawundi ye-cannabis, i-FDA yachaza kuhlaziyo lwayo.

Iingozi ezinokuthi zenzeke kwi-CBD

I-CBD kunokuba lula ukuyithenga kwezi ntsuku, kodwa i-FDA ikhumbuza abathengi ukuba ezi mveliso zisalawulwa kakhulu, zisenza kube nzima ukufumanisa ukuba zichaphazela njani umzimba womntu.

Kuhlaziyo olutsha lomthengi, i-FDA ichaze iinkxalabo ezithile zokhuseleko, kubandakanya ukonakala kwesibindi, ukozela, urhudo, kunye notshintsho kwiimvakalelo. I-arhente ikwaphawule ukuba izifundo ezibandakanya izilwanyana zicebise ukuba i-CBD inokuphazamisa ukukhula kunye nokusebenza kwamatyhalarha kunye nesidoda, esinokuthi sinciphise amanqanaba e-testosterone kunye nokuphazamisa ukusebenza ngokwesondo emadodeni ngenxa yoko. (Okwangoku, i-FDA ithi akucaci ukuba ezi ziphumo ziyasebenza na ebantwini.)

Uhlaziyo lukwachaza ukuba khange kubekho uphando olwaneleyo malunga nempembelelo ye-CBD enokuba nayo kwabasetyhini abakhulelweyo nabancancisayo. Okwangoku, iarhente "icebisa kakhulu ngokuchasene" nokusebenzisa i-CBD-kunye nentsangu nangaluphi na uhlobo, ngalo nto-ngexa lokukhulelwa okanye xa uncancisa. (Idibeneyo: Nguwuphi umahluko phakathi kwe-CBD, i-THC, iCannabis, iMarijuana kunye neHemp?)

Okokugqibela, uhlaziyo lomthengi olutsha lwe-FDA lulumkisa kakhulu malunga nokusetyenziswa kwe-CBD ukunyanga iimeko zempilo ezinokuthi zifune unyango okanye ungenelelo olunzulu: "Abathengi banokuyeka ukufumana unyango olubalulekileyo, olufana nokuxilongwa okufanelekileyo, unyango kunye nokhathalelo oluxhasayo ngenxa yamabango angaxhaswanga Iimveliso ze-CBD, "inqaku leendaba malunga nohlaziyo lwabathengi lwaphawula. "Ngenxa yeso sizathu, kubalulekile ukuba abathengi bathethe noononophelo lwempilo malunga neyona ndlela yokunyanga izifo okanye iimeko ngeendlela esele zikho, ezivunyiweyo zonyango."

I-FDA isaphula njani i-CBD

Ngenxa yokunqongophala kwedatha yesayensi kukhuseleko lwe-CBD, i-FDA ithi ikwathumele iileta ezilumkisayo kwiinkampani ezili-15 ngoku ezithengisa ngokungekho mthethweni iimveliso ze-CBD eMelika.

Uninzi lwezi nkampani zonke izinto ezingenabungqina zithi iimveliso zazo "ziyathintela, zichonge, zinciphise, zinyange okanye ziphilise izifo ezinzulu, ezinje ngomhlaza," eyaphula umthetho ofundwayo weFederal Food, Drug, and Cosmetic Act, ngokokuhlaziywa kwabathengi be-FDA.

Ezinye zezi nkampani zikwathengisa i-CBD njengesongezelelo sokutya kunye / okanye isongezo sokutya, ethi i-FDA ithi akukho semthethweni-ixesha. "Ngokusekwe kukunqongophala kolwazi lwenzululwazi oluxhasa ukhuseleko lwe-CBD ekutyeni, i-FDA ayinakho ukugqiba ukuba i-CBD ibonwa njengekhuselekileyo (GRAS) phakathi kweengcali ezifanelekileyo ekusetyenzisweni kwayo ekutyeni kwabantu okanye kwezilwanyana," ifunda ingxelo evela kumaphephandaba e-FDA. ukukhulula.

"Izenzo zanamhlanje ziza njengoko i-FDA iqhubeka nokuphonononga iindlela ezinokubakho zeentlobo ezahlukeneyo zeemveliso ze-CBD ukuba zithengiswe ngokusemthethweni," iqhubekile ingxelo. "Oku kubandakanya umsebenzi oqhubekayo wokufumana kunye nokuvavanya ulwazi lokujongana nemibuzo engekaphendulwa enxulumene nokhuseleko lweemveliso ze-CBD ngelixa kugcinwa imigangatho yempilo yoluntu engqingqwa."

Yintoni omele uyazi Ukuqhubela phambili

Kubalulekile ukuba uqaphele ukuba ukusukela namhlanje, kukho kuphela Nye Imveliso ye-CBD evunyiweyo yi-FDA, kwaye ibizwa ngokuba yi-Epidiolex. Amayeza amiselweyo asetyenziselwa ukunyanga iindlela ezimbini ezinqabileyo kodwa ezinzima zesifo sokuwa kubantu abaneminyaka emibini ubudala nangaphezulu. Ngelixa ichiza lincedile abaguli, i-FDA yalumkisa kuhlaziyo lomthengi wayo omtsha ukuba enye yeempembelelo zonyango ibandakanya ukubakho komngcipheko wokulimala kwesibindi. Nangona kunjalo, iarhente igqibe ekubeni "umngcipheko ungaphezulu kunezibonelelo" kwabo bathatha amayeza, kwaye le mingcipheko inokulawulwa ngokukhuselekileyo xa iyeza lithathwa phantsi kweliso lonyango, ngokuhlaziywa kwabathengi.

Okukwintsusa? Ngaphandle kokuba i-CBD isengumkhwa wokuphila kakuhle, kusekho ezininzi engaziwayo emva kwemveliso kunye nobungozi bayo. Oko kuthethiweyo, ukuba usenokholo kwi-CBD kunye nezibonelelo zayo, kufanelekile ukufunda indlela yokuthenga iimveliso ezikhuselekileyo nezisebenzayo kangangoko.

Uphengululo lwe